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Abstract
The central mechanisms through which 3,4-methylenedioxymethamphetamine
(MDMA) mediates life-threatening hyperthermia when taken in a warm envi-
ronment are not well described. It is assumed that MDMA alters normal ther-
moregulatory circuits resulting in increased heat production through
interscapular brown adipose tissue (iBAT) and decreased heat dissipation
through cutaneous vasoconstriction. We studied the role of the dorsomedial
hypothalamus (DMH) and medullary raphe pallidus (mRPa) in mediating
iBAT, tail blood flow, and locomotor effects produced by MDMA. Rats were
instrumented with guide cannulas targeting either the DMH or the mRPa brain
regions involved in regulating iBAT and cutaneous vascular beds. In all animals,
core temperature and locomotion were recorded with surgically implanted tele-
metric transmitters; additionally, either iBAT temperature (via telemetric trans-
mitter) or tail artery blood flow (via tail artery Doppler cuff) were also
recorded. Animals were placed in an environmental chamber at 32°C and micr-
oinjected with either control or the gamma-aminobutyric acid (GABA) agonist
muscimol (80 pmol) followed by an intravenous injection of saline or MDMA
(7.5 mg kg1). To prevent undue suffering, a core temperature of 41°C was
chosen as the surrogate marker of mortality. Inhibition of the DMH, but not
the mRPa, prevented mortality and attenuated hyperthermia and locomotion.
Inhibition of either the DMH or the mRPa did not affect iBAT temperature
increases or tail blood flow decreases. While MDMA increases iBAT thermogen-
esis and decreases heat dissipation through cutaneous vasoconstriction, thermo-
regulatory brain regions known to mediate these effects are not involved.
Rather, the finding that inhibiting the DMH decreases both locomotion and
body temperature suggests that locomotion may be a key central contributor to
MDMA-evoked hyperthermia.
Abbreviations
MDMA, 3,4-methylenedioxymethamphetamine; DMH, dorsomedial hypothalamus;
mRPa, medullary raphe pallidus; iBAT, interscapular brown adipose tissue; aCSF,
artificial cerebrospinal fluid; ANOVA, analysis of variance.
Introduction
Amphetamine-type stimulants are among the most abused
drugs in the world. Ranked second only to cannabis, they
are currently used more than cocaine and heroin combined
(UNODC 2012). Of the many complications related to
amphetamine use, one of the most acute and life-threaten-
ing is severe hyperthermia. A large number of hyperthermia
and heatstroke cases have occurred with use of the substi-
tuted amphetamines like 3,4-methylenedioxymethamphet-
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amine (MDMA) (Henry 1992; Milroy et al. 1996; Liechti
et al. 2005). The severity of hyperthermia is directly linked
with adverse clinical outcomes, with one series showing
that death occurred in two-thirds of the cases when core
temperatures exceed 41.5°C (Gowing et al. 2002).
The mechanisms by which MDMA causes hyperthermia
are complex, but are thought to involve increased heat
generation through interscapular brown adipose tissue
(iBAT) combined with decreased heat dissipation through
the constriction of cutaneous blood vessels (Pedersen and
Blessing 2001; Blessing et al. 2006). MDMA also causes
spontaneous activity in rodents (Spanos and Yamamoto
1989) that may also contribute to hyperthermia and tox-
icity. Ambient temperature has a profound effect on tem-
perature responses to MDMA. When given in a cold
environment MDMA causes hypothermia, in a thermo-
neutral environment it can cause either hypo- or hyper-
thermia, and in a hot environment it causes hyperthermia
(Dafters 1994; Malberg and Seiden 1998). This is of par-
ticular importance to humans, as MDMA is often used to
facilitate dancing at both nightclubs and outdoor summer
events where ambient temperatures can be elevated
(Irvine et al. 2006). Ambient temperature may also affect
the treatment of hyperthermia from MDMA. Many drugs
that prevent hyperthermia and neurotoxicity from
MDMA at room temperature fail to do so when environ-
mental temperatures are elevated (Malberg et al. 1996;
Colado et al. 1998, 1999). Therefore, understanding the
mechanisms by which MDMA causes hyperthermia in a
warm environment is an important step in designing
effective treatment strategies.
The mechanisms through which MDMA increases sym-
pathetic outflow to iBAT and cutaneous vessels, and
increases spontaneous locomotion, involve a number of
neurotransmitters (e.g., serotonin, norepinephrine, and
dopamine) and their corresponding receptors (e.g., 5-
HT1A, 5-HT2A, alpha-1, D2, D1). (Callaway et al. 1992;
Mechan et al. 2002; Sprague et al. 2004, 2005; Blessing
et al. 2006; Risbrough et al. 2006; Rusyniak et al. 2007,
2008a; Vanattou-Saifoudine et al. 2010a,b). There has also
been data implicating Beta-3 receptors and skeletal muscle
uncoupling protein-3 in MDMA-mediated hyperthermia
in both rodents and humans (Mills et al. 2003; Sprague
et al. 2005; Hysek et al. 2013b). Despite the work done to
date, the brain regions regulating the responses to MDMA
are still largely unknown. Potential sites include brain
regions involved in thermoregulation. Two candidates are
the dorsomedial hypothalamus (DMH) and the medullary
raphe pallidus (mRPa). The mRPa is the site of premotor
neurons regulating sympathetic outflow to iBAT and
cutaneous vessels. It has been implicated in vasoconstric-
tion and iBAT thermogenesis from cold exposure, infec-
tion, and stress (DiMicco et al. 2006; Rathner et al. 2008;
Nakamura 2011). The DMH sends projections to the
mRPa and has likewise been reported to be involved with
control of iBAT thermogenesis and the regulation of cuta-
neous vascular beds (Zaretskaia et al. 2002; DiMicco and
Zaretsky 2007; Yoshida et al. 2009). We have shown that
the DMH is associated with the development of hyper-
thermia and hyperactivity from MDMA at room tempera-
ture (Rusyniak et al. 2008b).
It is not known whether the DMH and the mRPa are
involved in mediating iBAT and cutaneous vascular
responses to MDMA at warm ambient temperatures. This
study sought to determine the role of the DMH and the
mRPa in mediating iBAT, cutaneous vascular and loco-
motor responses to MDMA in conscious rats at an ele-
vated ambient temperature.
Materials and Methods
Chemicals
The NIH generously provided MDMA ( 3,4-methylenedi-
oxymethamphetamine HCl), which was dissolved in saline
for all experiments. All injection volumes were 1 mL kg1
body weight. Muscimol (Sigma-Aldrich, St. Louis, MO)
was dissolved in artificial cerebrospinal fluid (aCSF) and
stored at 20°C until the time of the experiment.
Animals
The care and use of rats were in accordance with proto-
cols approved by the Indiana University Animal Care and
Use Committee and in accordance with ARRIVE guide-
lines. Experiments were carried out under the supervision
of veterinarians. We used single-housed male Sprague-
Dawley rats (weight 300  20 g; Harlan, Indianapolis,
IN) that were maintained in a 12 h light/dark cycle and
fed ad libitum. A total of 110 of rats were used. We con-
ducted the experiments on fully conscious rats in isolated
quiet rooms between 10:00 AM and 4:00 PM using Raturn
cages (BASi, West Lafayette, IN); by rotating in the oppo-
site direction the rat moves, the cages allowed for the
measurement of tail blood flow without the need for an
electrical swivel. We kept the rats in the Raturn for a
minimum of 12 h before experiments, including an over-
night stay during their active cycle to acclimate them.
Surgical preparation
All animals underwent two consecutive surgeries. We
anesthetized animals with 1.5–2% isoflurane in oxygen,
adjusting the concentration of isoflurane as needed and
monitored heart rate and oxygen saturation during sur-
gery using a Pulse Oximeter monitor (model LS1P-10R;
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Nonin, Plymouth, MN). In the first surgery, we placed
either bilateral guide cannulas targeting the DMH, or a
single guide cannula targeting the midline mRPa. After
surgery, the animals recovered for 7 days. In the second
surgery, we implanted either a telemetric probe measuring
temperature of the iBAT and core body temperature (TT-
F40; Data Sciences International, St. Paul, MN), or we
placed an ultrasound Doppler probe measuring tail arte-
rial blood flow and a telemetric probe measuring core
body temperature (T-F40; Data Sciences International).
During the second surgery we also placed jugular venous
catheters, to allow for systemic drug administration.
Guide cannulas
We anesthetized animals and placed them in a stereotaxic
apparatus with the incisor bar set at 3.3 mm below the
interaural line. The skin overlying the dorsal surface of the
skull was pretreated with lidocaine/epinephrine mixture,
cut, and retracted followed by removal of soft tissue to
expose the surface of the skull. We treated the skull with a
30% hydrogen peroxide solution using cotton-tipped
applicators. This stopped bleeding, aided in sterility, and
enhanced the visibility of structures used as stereotaxic
landmarks. Central nervous system (CNS) targets had the
following coordinates according to a Rat Brain Atlas (Paxi-
nos and Watson 1998):
• DMH – using bregma as a reference point: AP (anterior
posterior) 3.1 mm; LR (left right) 2.0 mm; HD
(height depth) 8.2 mm. We used a 10-degree angle
from the sagittal plane to avoid central sinus and to
allow bilateral placement of two cannulas.
• mRPa – using the interaural point as a reference point:
AP 2.8 mm, LR 0 mm, HD 1.1 mm.
Using a rotary tool (MiniMite Cordless 4.8V; Dremel,
Racine, WI) equipped with a surgical carbide burr
(DHP557; Miltex, Plainsboro, NJ), we made a small hole in
the skull. We inserted the cannulas (26 gauge; Plastics One,
Roanoke, VA) through the holes, and positioned them to
target appropriate CNS sites. We placed two jeweler’s
screws (size 80) into the skull to facilitate attachment of the
cement cap. Once inserted, we secured the cannulae using
Vetbond glue (3M, St. Paul, MN) and cranioplastic cement.
We inserted dummy-wire cannulas into the guides and
returned the rats to their home cages for recovery.
Intravenous (i.v.) catheter implantation
A week later, we implanted jugular vein catheters to allow
for the systemic administration of drugs. Rats were placed
in a sterile surgery field in a dorsal recumbent position
exposing the neck and shoulder area. A small longitudinal
incision was made rostral to the clavicle and the jugular
vein was dissected and ligated. We inserted a catheter,
constructed of 3.5 cm Silastic tubing (508-007; Dow
Corning, Midland, MI) connected to 10 cm of Tygon
tubing (Small Parts Inc., Miami, FL,) with 1 cm of PE-50
tubing (Plastics One). The catheter was filled with saline
and inserted, Silastic end first, ~3 cm into the vein. We
then routed the catheter subcutaneously, exteriorizing it
at the dorsal neck area. We flushed the catheter, capped it
with a metal plug, and secured it to the skin with sutures.
To prevent the catheter from being chewed, we looped it
either through a rodent saddle (INFU-SDL1; Kent Scien-
tific Corporation, Torrington, CT), which also held the
externalized connection for tail flow probe, or to the rat
collar, which connects the rat to the Raturn (BASi).
Temperature telemetric probes
After inserting jugular catheters, we placed animals in the
ventral recumbent position to expose their back. In order
to implant the dual thermistor telemetry transmitters (TT
F40) to measure iBAT temperature we made two longitu-
dinal skin incisions: a medial incision in the interscapular
area for iBAT measurement; and another slightly aside of
midline several centimeters posterior to the first to house
the body of the transmitter and to tunnel the peritoneal
temperature probe. We placed the tip of the iBAT therm-
istor under the left lobe of the iBAT through a small inci-
sion made through the connective tissue, and secured the
catheter in place with a purse-string suture. We tunneled
the peritoneal thermistor subcutaneously to a small cuta-
neous incision on the side of the abdominal cavity. The
tip was placed into the abdominal cavity through the
incision, and fixed to the muscle wall with purse-string
suture. We sutured the skin incisions closed and applied
a topical antibiotic ointment. Animals were returned to
their cage and allowed to recover at least 1 week.
In the experiments measuring Doppler flow, we mea-
sured core temperature with an implanted telemetry
thermistor (T-F40). After inserting jugular catheters, we
placed animals in a dorsal recumbent position with
abdominal skin shaved along midline. We made a 2 cm-
long longitudinal medial skin incision, followed by a lon-
gitudinal incision of the muscular wall along the white
line. We inserted the body of the transmitter into the
abdominal cavity and sutured the muscle closed followed
by the skin. Animals were returned to their cage for at
least 1 week before experimentation.
Doppler cuffs
To measure tail artery blood flow we implanted a Doppler
ultrasonic flow probe (Iowa Doppler Products, Iowa City,
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IA) around the proximal portion (~3 cm from the base)
using slightly modified methods we have previously
reported (Rusyniak et al. 2008a). Briefly, we placed
anesthetized animals on their back in a sterile surgery field
with the base of the tail area exposed. We made a cutaneous
longitudinal incision ~1–2 cm caudally to the anus. After
exposing the tail artery and placing the cuff around it, we
tunneled the wires through tendons above the bone per-
pendicular to the artery. We stabilized the artery cuff using
sutures and Vetbond glue around the polyvinyl chloride
cover of the wire. We closed the connective tissues above
the cuff with sutures and routed the wires subcutaneously
to the base of the neck were they were externalized. The
skin was closed with sutures. To prevent the wires from
being chewed or pulled, we looped them through a rodent
saddle. We then soldered the ends of the wires to a small
three-pronged adapter (SM3H, SMH; Powell Electronics,
Inc., Swedesboro, NJ) that connects to a Doppler flowmeter
(Iowa Doppler). We capped the adapter and lightly fixed it
to the saddle between experiments. We calculated blood
flow from the flowmeter output voltage using a formula
provided by the manufacturer.
Testing functionality of sensors
Before conducting iBAT experiments, we established that
the iBAT probe and tail blood flow sensors were working
properly. After rats were acclimated overnight at room
temperature, over 40–60 min, we increased the ambient
temperature to 32°C. We confirmed that animals at this
temperature developed a sustained tail blood flow
increase (at least 20 cm sec1 maximal amplitude). After-
ward, we lowered the ambient temperature to 10°C. Pre-
viously, we defined a correctly placed iBAT sensor if
cooling increased the iBAT temperature at least 0.5°C
(Rusyniak et al. 2008a). Furthermore, we confirmed that
the tail blood flow probe was considered properly func-
tioning if flow decreased to <5 cm sec1 at 10°C.
Experimental protocol
Using a custom built environmental chamber we con-
ducted experiments at an ambient temperature of 32°C as
this temperature was easy to reach and maintain, caused
a sustained vasodilation at baseline (making it easier to
detect drug-induced vasoconstriction), is in the range of
temperatures which others have reported hyperthermia
with MDMA in rats (Gordon et al. 1991), and is similar
to ambient temperatures at outdoor events in the United
States (Cavaliere 2013), which were linked to deaths from
MDMA use.
In an initial pilot study, we noticed that after receiving
7.5 mg/kg (i.v.) of MDMA, several animals died shortly
after their body temperature approached or exceeded
42°C. To prevent animal suffering, we chose 41°C as a
surrogate marker of mortality. This allowed us to stop the
experiment and quickly remove the animal from the tem-
perature chamber and cool them. No animals died during
the experiment using this protocol.
To investigate whether the DMH and or the mRPa par-
ticipate in MDMA-mediated increases in iBAT thermo-
genesis and cutaneous vasoconstriction, we conducted the
following experiment. After rats were acclimating in the
Raturn overnight we increased the ambient temperature
from 24  0.5°C to 32  0.5°C. Once ambient tempera-
tures stabilized, we connected microinjectors (33 gauge;
Plastics One) to a 10 µl Hamilton syringe with Teflon
tubing (ID 0.12 mm; OD 0.65 mm; BASi), and placed
microinjectors in the guide cannulas. The syringes were
mounted on an infusion pump (Model 200, KD Scien-
tific, Holliston, MA) capable of delivering, over 30 sec, a
100 nL solution of either vehicle (aCSF) or muscimol
(80pmol). We left animals undisturbed for at least 1 h to
reduce changes in temperature and tail blood flow related
to the stress of placing the injectors (Zaretsky et al.,
2011). After this, we microinjected animals with either
muscimol or vehicle followed 5 min later by an i.v. injec-
tion of either MDMA (7.5 mg kg1) or saline. We chose
the dose of 7.5 mg kg1of MDMA as it causes tempera-
ture responses reported in moderate to severe cases of
human intoxication, and results in plasma concentrations
similar to those seen in humans taking recreational doses
(Green et al. 2009). We chose the i. v. route as it avoids
the stress seen with intraperitoneal and subcutaneous
injections. This was important since microinjections of
muscimol in the mRPa and DMH, compared to CSF,
decrease stress responses (DiMicco et al. 2006). Therefore,
i.v. injections allowed us to better evaluate the role of the
mRPa in DMH in responses to MDMA independent of
the stress of the injections. In all experiments, physiologi-
cal parameters were recorded every minute until either a
core temperature reached 41°C, or for a total of 60 min
after last injection. We chose this time since the duration
of muscimol’s inhibitory action, for the dose and volume
in this study, is ~60 min (Zaretsky et al. 2003; Rusyniak
et al. 2007). A representative example of single experi-
ment can be seen in Figure 1.
Verification of injection sites
At the conclusion of each experiment, we injected rats
with pentobarbital (100 mg kg1 i.v.) and then transcar-
dially perfused them with 60 ml of cold saline (4°C) fol-
lowed by 60 ml of 4% paraformaldehyde. We excised the
brain and post fixed it in a 4% solution of paraformalde-
hyde overnight at 4°C. We then placed brains in a
2014 | Vol. 2 | Iss. 2 | e00031
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solution of 23% sucrose in PBS at 4°C until sectioning.
We cut coronal brain sections (40 lm) using a cryostat
(Leica Microsystems, Buffalo Grove, IL). An observer
blinded to group allocation determined the injection sites
by visualizing the injection track under light microscopy
in Neutral Red stained tissue sections.
Data analysis and statistical procedures
We conducted statistics and created graphs using Prism
(Graphpad Software, San Diego, CA) software. We
calculated survival using Kaplan–Meier curves plotting
the percent survival (animals with core temps <41°C)
over time. We compared groups using a log-rank
(Mantel–Cox) test. We compiled absolute core tempera-
ture values from both iBAT and tail experiments and
plotted the 5 min means. Since animals were removed
from the study at different time points (depending on
when and whether they reached a core temperature of
41°C), we only plotted the first 27.5 min of the experi-
ment (at this time no animal had been removed from
the study). We compared groups by conducting an
analysis of variance (ANOVA) analysis, with Tukey’s
post hoc analysis, on temperatures at 27.5 min. We
obtained locomotion data by converting the voltage out-
put of the Raturn to cage rotations per min – the Ra-
turn rotates at a speed of 31.5 rotations per minute.
As with core temperature, we compiled absolute loco-
motion values from both the iBAT and tail experiments
plotting the first 27.5 min and analyzing them at
27.5 min. Since baseline tail blood flow is more variable
between animals (likely secondary to slight differences in
placement and artery size), we plotted and compared
the percent change from baseline. As with temperature,
we plotted the first 27.5 min and analyzed the data at
27.5 min. To assess iBAT thermogenesis, we plotted the
difference between iBAT and core temperatures, and
analyzed these values in a manner similar to tempera-
ture.
Results
Location of injection sites
We confirmed the microinjection sites by identifying the
injection needle track under light microscopy. We esti-
mated the approximate centre of the injection site and
plotted it on schematic coronal sections in which the
DMH and mRPa were demarcated using a drawing
adapted from the atlas of Paxinos and Watson (1998).
The total area encompassing all the injections in the
region of the DMH and mRPa is shown in gray (Fig. 2A
and C). Injections into the DMH and the mRPa were
considered successful only if the centre of injection site
(or injection sites in the case of DMH) was within gray
rectangle. Seven animals (3 DMH, 4 mRPa) had injection
sites outside of these areas and were excluded from
analysis.
Effects of inhibiting the DMH or the mRPa
on survival rates in rats treated with MDMA
in a warm environment
Inhibition of the DMH significantly decreased the num-
ber of animals reaching a body temperature of 41°C, and
37.0
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iBAT
CoreiBAT and Core 
0
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Tail artery 
Doppler flow
 (cm sec-1)
0 20 40
0
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40
Minutes
Locomotion 
(rotations min-1)
MDMA 
(7.5 mg kg–1)
aCSF
Figure 1. The following data represent the 1-min means of iBAT,
Core temperature, and locomotion (obtained from one rat) and the
tail blood flow (100 Hz), from a separate rat. To make the
interpretation of the data more meaningful we chose two animals
with nearly identical core temperature responses. aCSF was
microinjected into the mRPa at T = 5 min and 7.5 mg kg1 MDMA
(7.5 mg kg1) was injected at t = 0 min. Ambient temp = 32°C.
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by extension, increased survival. In contrast, inhibition of
the mRPa had no effect on animal “survival”. As Figure 3
demonstrates the majority of animals microinjected with
aCSF, regardless of whether injected in the DMH or
mRPa, rapidly reached core temperatures of 41°C after
MDMA: All of the 12 animals microinjected with aCSF in
the mRPa and 14 of 16 animals (87.5%) microinjected
with aCSF in the DMH achieved temperatures of 41°C
before the end of a 60 min observation period. In con-
trast, only 5 of 14 (36%) of animals in the DMH Musc-
MDMA group developed temperatures of 41°C before the
end of the 60-min study period; All (16 of 16) of the
(A) (B)
(C) (D)
Figure 2. (A and C) show coronal brain sections, adapted from the Paxinos and Watson (1998) atlas, with the area in which all the DMH (A) and
all the mRPa (C) microinjections occurred depicted by the gray rectangles. (B and D) show a representative injection site of a DMH (B) and mRPa
(D) in individual rats.
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Figure 3. The figures represent Kaplan–Meyer survival curves for animals microinjected into the region of the DMH or mRPa with either aCSF or
muscimol (80 pmol, 100 nL) followed by an i.v injection of MDMA (7.5 mg kg1) at an ambient temp of 32°C. The x-axis represents time of
survival after injection of MDMA and the y-axis the percent of animals surviving. A core temperature of 41°C was used as a surrogate marker of
mortality and animals were removed from the study when they reached this temperature. Values in parentheses are the number of animals in
each group. Differences were determined using a log-rank (Mantel-Cox) test.
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mRPa Musc-MDMA group developed temperatures of
41°C before the end of the observation period.
Effects of inhibiting the DMH or the mRPa
on temperature and locomotor responses
mediated by MDMA in a warm environment
Independent of whether we had microinjected aCSF or
muscimol (80 pmol), and whether it was injected into the
DMH or mRPa, MDMA caused a significant increase in
core body temperature and locomotion at 30 min over
controls. Compared to aCSF, however, muscimol injected
into the DMH significantly reduced the increases in both
temperature (Fig. 4A) and locomotion (Fig. 4B). Micro-
injecting muscimol into the mRPa had no effect on the
development of hyperthermia or hyperactivity produced
by MDMA (Fig. 5A and B). Microinjection of muscimol
or saline into either the DMH or the mRPa, had no effect
on core temperature or locomotion after the administra-
tion of saline. Although we have previously shown that
inhibiting the mRPa (Zaretsky et al. 2003; Rusyniak et al.
2008b) and DMH decreases body temperature in control
animals, these studies were conducted at room
temperature. As we conducted this study at or above the
thermoneutral zone for Sprague Dawley rats, we would
not expect a decrease in core temperature (Gordon 1987).
Effects of inhibiting the DMH or the mRPa
on iBAT temperature and tail blood flow
responses mediated by MDMA in a warm
environment
As previously reported, the systemic injection of MDMA
increases iBAT thermogenesis while simultaneously
decreasing heat dissipation through vasoconstriction
(Blessing et al. 2006). We found that inhibiting either the
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Figure 4. (A and B) show the temperature and locomotion responses, respectively, after an i.v. injection of MDMA (7.5 mg kg1) or saline in
rats previously microinjected into the region of the DMH with either aCSF or muscimol (80 pmol, 100 nL). The line graphs on the left represent
the 5-min means for each group over time and the bar graphs on the right show the mean for the temperature and locomotion at 27.5 min.
Error bars represent SEMs. The number of animals in each group is shown in parentheses. The dashed vertical line denotes the time of
microinjection and the solid vertical line denotes the time of i.v. injection. *Significant difference (P < 0.05) from its corresponding control and
“#” significant (P < 0.05) difference between groups receiving MDMA. Differences were determined by ANOVA with a Tukey’s post hoc test.
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DMH or the mRPa had no effect on these responses
(Figs. 6 and 7). Microinjection of muscimol or saline into
either the DMH or the mRPa, had no effect on iBAT
temperature or tail blood flow after the administration of
saline.
Discussion and Conclusions
Our findings demonstrate that neurons in the DMH, not
the mRPa, mediate hyperthermia from MDMA. Further-
more, our data suggest that locomotion may be a key
central mechanism mediating hyperthermia. In our previ-
ous study we showed that inhibiting the DMH attenuated
both temperature and locomotor responses to MDMA
(Rusyniak et al. 2008b). These experiments, however,
were conducted at room temperature and resulted in peak
temperature responses well below those associated with
adverse outcomes in humans (Gowing et al. 2002). Fur-
thermore, our prior work did not determine if along with
decreasing locomotion, the DMH affected-iBAT and cuta-
neous vascular responses. Our present finding, that inhib-
iting the DMH decreased locomotion but had no effect
on tail blood flow or iBAT thermogenesis, suggests that
inhibition of locomotion alone might be sufficient to pre-
vent hyperthermia from MDMA. This is important when
viewed in the context that MDMA is commonly used at
dance parties and concerts where the combination of a
warm environment and exercise may be particularly dan-
gerous. This was made even more evident by a string of
deaths this summer at dance parties in the United States
associated with MDMA (Cavaliere 2013). While it is not
difficult to understand how skeletal muscle contractions
contribute to heat generation, it remains unclear why in
rats, and presumably in humans, MDMA motivates ani-
mals to continue to exert themselves even when core
body temperatures are critically elevated. Sports medicine
literature has shown that in both humans and rodents as
core temperatures approach 40°C study subjects become
exhausted and stop exercising (Fuller et al. 1998;
Gonzalez-Alonso et al. 1999). As evident in Figure 1, rats
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(B)
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Figure 5. (A and B) show the temperature and locomotion responses, respectively, after an i.v. injection of MDMA (7.5 mg kg1) or saline in
rats previously microinjected into the region of the mRPa with either aCSF or muscimol (80 pmol, 100 nL). The line graphs on the left represent
the 5-min means for each group over time and the bar graphs on the right show the mean for the temperature and locomotion at 27.5 min.
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continue running at a high rate even when core tempera-
tures are above 40°C. We chose 41°C as the temperature
to remove animals from the experiment, as some animals
in our pilot study appeared to literally run to death. This
suggests that key contributors to hyperthermia from
MDMA are spontaneous locomotion and the failure to
stop activity despite critical elevations in temperature.
While we showed that inhibiting the DMH decreases
locomotion, it remains unclear if the DMH is also
involved in centrally mediated exhaustion. It is important
to note that the DMH is a complex region of the brain
involved in a variety of physiologic functions. So while
our data show a strong association between locomotion
mediated through the DMH and MDMA-evoked hyper-
thermia, further work is needed to confirm this link.
If locomotion is a significant contributor to MDMA
hyperthermia, it is contrary to what others, including
ourselves, have previously published (Dafters 1995; Green
et al. 2004; O’Shea et al. 2005; Rusyniak et al. 2007;
Docherty and Green 2010). These prior assertions were
largely based on the fact that MDMA caused similar
amounts of locomotion in a cold and warm environment
but opposite temperature responses (Dafters 1994, 1995).
The lack of correlation between locomotor activity and
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Figure 6. (A and B) show the difference between iBAT and core temperature and the change from baseline in tail Doppler blood flow,
respectively, after an i.v. injection of MDMA (7.5 mg kg1) or saline in rats previously microinjected into the region of the DMH with either aCSF
or muscimol (80 pmol, 100 nL). The line graphs on the left represent the 5-min means for each group over time and the bar graphs on the right
show the mean for the iBAT – Core at 27.5 min and tail blood flow at 2.5 and 27.5 min. Error bars represent SEMs. The number of animals in
each group is represented in parentheses. The dashed vertical line denotes the time of microinjection and the solid vertical line denotes the time
of i.v. injection. *Significant difference (P < 0.05) from its corresponding control. Differences were determined by ANOVA with a Tukey’s post hoc
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core temperature does not, however, mean that locomo-
tion is not a significant contributor to hyperthermia. A
corollary to this is a marathon. While the distance run is
the same whether the event is held on a cold or warm
day, the risk for exertional heat stroke is greater in warm.
This does not mean, however, that the heat generated by
running does not contribute to heat stroke. What previ-
ous rat studies with MDMA, which suggest locomotion
does not contribute to hyperthermia, may not account
for is that heat dissipation will be more efficient in a cold
or cool environment than a warm environment. This
would be expected to affect not only radiant heat loss
through skin but also evaporative heat loss by saliva
spreading (Hainsworth 1967), as well as loss of heat
through respiration (both heat transfer and evaporation).
Therefore, heat stroke from MDMA occurs when heat
generation is greater than heat dissipation.
The assumption that locomotion does not contribute
to hyperthermia from MDMA has led to the belief that
thermogenesis from MDMA was mediated primarily
through nonshivering thermogenesis (via iBAT and
possibly skeletal muscle). This idea is supported by data
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Figure 7. (A and B) show the difference between iBAT and core temperature and the change from baseline in tail Doppler blood flow,
respectively, after an i.v. injection of MDMA (7.5 mg kg1) or saline in rats previously microinjected into the region of the mRPa with either aCSF
or muscimol (80 pmol, 100 nL). The line graphs on the left represent the 5-min means for each group over time and the bar graphs on the right
show the mean for the iBAT – Core at 27.5 min and tail blood flow at 2.5 and 27.5 min. Error bars represent SEMs. The number of animals in
each group is shown in parentheses. The dashed vertical line denotes the time of microinjection and the solid vertical line denotes the time of i.v.
injection. *Significant difference (P < 0.05) from its corresponding control. Differences were determined by ANOVA with a Tukey’s post hoc test.
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showing that drugs that decrease hyperthermia from
MDMA also decrease nonshivering thermogenesis. Cloza-
pine, for instance, decreases hyperthermia from MDMA
and has also been shown to decrease iBAT thermogenesis
(Blessing et al. 2006). Clozapine, however, also decreases
locomotion produced by MDMA (Kehne et al. 1996). In
fact, the majority of compounds that have been shown to
decrease or prevent hyperthermia induced by MDMA also
decrease locomotion – e.g., the 5-HT-2A antagonists M
100907; the D2 antagonist haloperidol; the D1 antagonist
SCH 23390; and the alpha-1 antagonist prazosin (Kehne
et al. 1996; Fantegrossi et al. 2004). While nonshivering
thermogenesis likely contributes to hyperthermia pro-
duced by MDMA, it may not be the primary means by
which heat is generated.
MDMA impairs heat dissipation. Our data, similar to
what others have reported, show that MDMA causes
vasoconstriction. In this study, vasoconstriction was max-
imum immediately after the MDMA was administered
and returned to baseline by 30 min. This is different
from what others have reported with MDMA. In their
article, Blessing et al. 2003 showed sustained reductions
in tail blood flow for as long as 90 min after the injec-
tion. There are several factors that might account for
these differences. They conducted their experiments
between 26°C and 28°C, while we conducted our studies
at 32°C. In their graphs, core temperature rises slowly
and does not exceed 40°C. Since our experiments were
conducted at a higher temperature, our rats had higher
core and skin temperatures. This may have increased the
peripheral and central afferent signals activating warm-
sensitive neurons causing vessels to vasodilate sooner.
Another difference with this study is the route of admin-
istration. We administered MDMA i.v., which would cre-
ate higher blood concentrations that more rapidly
distribute out of the vascular system. This could explain
our rapid responses and recovery. In addition, i.v. admin-
istration would eliminate drug first-pass effect; as MDMA
has numerous active metabolites this could also account
for differences seen in this study (Baumann et al. 2009).
Independent of this, our data clearly show that even
though vasoconstriction returned to baseline levels by
30 min, core temperatures in these animals continued to
rise. This suggests that in our experiments heat genera-
tion contributes more to a core temperature change than
impaired heat dissipation.
Another surprising finding in our data is that MDMA-
mediated increases in iBAT thermogenesis, and decreases
in tail blood flow, were not mediated by neurons in either
the DMH or mRPa. These data clearly demonstrate that
hyperthermia mediated by MDMA is not the result of
altering thermoregulatory circuits in the brain as has been
previously suggested (Hargreaves et al. 2007; Benamar
et al. 2008). Rather, our data suggest that monoamines
released by MDMA act either directly at the level of the
spinal cord or peripherally on blood vessels and iBAT.
Ootsuka et al. (2004) showed that inhibiting neurons in
the region of the mRPa, in anesthetized rabbits, did not
prevent increases in sympathetic outflow to the ear caused
by MDMA. Increases in sympathetic nerve activity were,
however, reversed by the systemic injection of SR46349B,
a 5-HT2A antagonist. They suggested that MDMA medi-
ates its cutaneous effects through serotonin receptors in
the spinal cord. These experiments, however, were con-
ducted in anesthetized animals and the effect on blood
flow was not measured. Our data are the first to measure
the effect of inhibiting brain regions on tail blood flow in
a conscious freely moving animal. Whether or not
MDMA is acting at the level of the spinal cord requires
further research. It is also possible that MDMA could
have direct effects on tail vasoconstriction. In the rat
MDMA has weak agonist properties on numerous adren-
ergic receptors in rats, including alpha-1, alpha-2, trace
amine, and 5-HT2A (Nash et al. 1994; Bexis and Docherty
2006) (Broadley et al. 2013). Although these effects are
relatively weak, at high doses, similar to those in our
studies, it is possible that MDMA may directly constrict
cutaneous vessels through these receptors, which are also
located on vascular smooth muscle and cause vasocon-
striction (Villal€on and Centuri€on 2007). If MDMA causes
direct vasoconstriction in humans, it is most likely
through 5-HT2A receptors (Liechti et al. 2000). In both
humans and rodents, MDMA has also been shown to
cause large increases in circulating levels of norepineph-
rine and epinephrine, which can cause vasoconstriction
through alpha-1 receptors (Sprague et al. 2005; Hysek
et al. 2011, 2013a).
In conclusion, this study suggests that locomotion med-
iated by MDMA, through neurons located in the DMH,
may contribute to fatal hyperthermia in warm environ-
ment. If true, drugs or strategies that decrease locomotion
may prevent mortality. Confirming the role of locomo-
tion, and the central mechanisms through which it is con-
trolled, is an important next step in understanding how
MDMA causes temperature-related deaths.
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